Structure-Function Analyses of New SARS-CoV-2 Variants B.1.1.7, B.1.351 and B.1.1.28.1: Clinical, Diagnostic, Therapeutic and Public Health Implications.
501Y.V1
501Y.V2
B.1.1.28.1
B.1.1.7
B.1.351
COVID-19 vaccines
Clade G
D614G variant
ORF8
P.1
furin cleavage site
immune escape
public health strategies
spike protein
vaccine delivery
Journal
Viruses
ISSN: 1999-4915
Titre abrégé: Viruses
Pays: Switzerland
ID NLM: 101509722
Informations de publication
Date de publication:
09 03 2021
09 03 2021
Historique:
received:
27
01
2021
revised:
28
02
2021
accepted:
03
03
2021
entrez:
3
4
2021
pubmed:
4
4
2021
medline:
20
4
2021
Statut:
epublish
Résumé
SARS-CoV-2 (Severe Acute Respiratory Syndrome-Coronavirus 2) has accumulated multiple mutations during its global circulation. Recently, three SARS-CoV-2 lineages, B.1.1.7 (501Y.V1), B.1.351 (501Y.V2) and B.1.1.28.1 (P.1), have emerged in the United Kingdom, South Africa and Brazil, respectively. Here, we have presented global viewpoint on implications of emerging SARS-CoV-2 variants based on structural-function impact of crucial mutations occurring in its spike (S), ORF8 and nucleocapsid (N) proteins. While the N501Y mutation was observed in all three lineages, the 501Y.V1 and P.1 accumulated a different set of mutations in the S protein. The missense mutational effects were predicted through a COVID-19 dedicated resource followed by atomistic molecular dynamics simulations. Current findings indicate that some mutations in the S protein might lead to higher affinity with host receptors and resistance against antibodies, but not all are due to different antibody binding (epitope) regions. Mutations may, however, result in diagnostic tests failures and possible interference with binding of newly identified anti-viral candidates against SARS-CoV-2, likely necessitating roll out of recurring "flu-like shots" annually for tackling COVID-19. The functional relevance of these mutations has been described in terms of modulation of host tropism, antibody resistance, diagnostic sensitivity and therapeutic candidates. Besides global economic losses, post-vaccine reinfections with emerging variants can have significant clinical, therapeutic and public health impacts.
Identifiants
pubmed: 33803400
pii: v13030439
doi: 10.3390/v13030439
pmc: PMC8000172
pii:
doi:
Substances chimiques
Antibodies, Neutralizing
0
Antibodies, Viral
0
Coronavirus Nucleocapsid Proteins
0
Spike Glycoprotein, Coronavirus
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Références
Open Forum Infect Dis. 2020 Nov 24;8(1):ofaa559
pubmed: 34164560
Science. 2020 Aug 7;369(6504):650-655
pubmed: 32571838
Sci Immunol. 2020 Dec 7;5(54):
pubmed: 33288645
Clin Infect Dis. 2021 Nov 2;73(9):e2823-e2825
pubmed: 32964927
PLoS Pathog. 2020 Dec 7;16(12):e1009130
pubmed: 33284849
Lancet. 2021 Feb 6;397(10273):452-455
pubmed: 33515491
Cell Host Microbe. 2020 Sep 9;28(3):497
pubmed: 32910920
Nat Commun. 2020 Sep 4;11(1):4420
pubmed: 32887876
Nucleic Acids Res. 2008 Jul 1;36(Web Server issue):W229-32
pubmed: 18424796
ACS Cent Sci. 2020 Oct 28;6(10):1722-1734
pubmed: 33140034
Cell. 2020 Apr 16;181(2):271-280.e8
pubmed: 32142651
J Biol Chem. 2019 May 17;294(20):8064-8087
pubmed: 30824541
Elife. 2020 Oct 28;9:
pubmed: 33112236
Lancet Infect Dis. 2021 May;21(5):602
pubmed: 33571446
Science. 2021 Feb 19;371(6531):850-854
pubmed: 33495308
Nature. 2021 Apr;592(7852):116-121
pubmed: 33106671
Nanoscale. 2020 Aug 21;12(31):16409-16413
pubmed: 32725017
J Mol Graph. 1996 Feb;14(1):33-8, 27-8
pubmed: 8744570
Materials (Basel). 2020 Nov 26;13(23):
pubmed: 33255977
J Comput Aided Mol Des. 2013 Mar;27(3):221-34
pubmed: 23579614
Indian J Med Res. 2020 May;151(5):474-478
pubmed: 32474554
Nat Med. 2021 Apr;27(4):622-625
pubmed: 33654292
Protein Sci. 2020 Jan;29(1):247-257
pubmed: 31693276
Nat Genet. 2020 Oct;52(10):999-1001
pubmed: 32908256
Infect Genet Evol. 2020 Oct;84:104384
pubmed: 32473976
Cell. 2020 Aug 20;182(4):812-827.e19
pubmed: 32697968
J Clin Microbiol. 2020 Dec 17;59(1):
pubmed: 33067272
New Microbes New Infect. 2020 Jul;36:100696
pubmed: 32509310
Nat Med. 2021 Apr;27(4):620-621
pubmed: 33558724
Cell Mol Immunol. 2020 Sep;17(9):998-1000
pubmed: 32728199
BMJ. 2021 Jan 18;372:n158
pubmed: 33462092
Lancet. 2021 Jan 9;397(10269):92-93
pubmed: 33347811
J Chem Theory Comput. 2019 Mar 12;15(3):1863-1874
pubmed: 30768902
Lancet Glob Health. 2020 Sep;8(9):e1132-e1141
pubmed: 32673577
Infect Genet Evol. 2020 Oct;84:104330
pubmed: 32335334
Cell. 2021 Mar 4;184(5):1171-1187.e20
pubmed: 33621484
Int J Infect Dis. 2020 Nov;100:216-223
pubmed: 32841689
Cell. 2020 Sep 3;182(5):1295-1310.e20
pubmed: 32841599
Protein Eng. 1995 Feb;8(2):127-34
pubmed: 7630882
Front Pharmacol. 2020 Dec 14;11:615211
pubmed: 33381049
Nature. 2020 Dec;588(7839):682-687
pubmed: 33045718
N Engl J Med. 2021 May 20;384(20):1885-1898
pubmed: 33725432
Science. 2020 Dec 18;370(6523):1464-1468
pubmed: 33184236
BMJ. 2020 Dec 16;371:m4857
pubmed: 33328153
Nature. 2021 May;593(7857):130-135
pubmed: 33684923
Proteins. 2007 Oct 1;69(1):139-59
pubmed: 17598144
Proc Natl Acad Sci U S A. 2021 Jan 12;118(2):
pubmed: 33361333
Nucleic Acids Res. 2005 Jul 1;33(Web Server issue):W363-7
pubmed: 15980490
Nat Rev Immunol. 2020 Jul;20(7):408
pubmed: 32504060